Tasly Transgene Biopharmaceuticals (Tianjin) Co. Ltd. announced that it will receive an equity round of funding on December 2, 2016. The transaction will include participation from a returning investor, Tasly Pharmaceutical Group Co., Ltd. (SHSE:600535) and a French party. The transaction was approved in the 12th session of the 6th directorate meeting of Tasly Pharmaceutical Group Co., Ltd.